Neostigmine/Glycopyrrolate for Neuromuscular Blockade

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Neuromuscular Blockade+1 Moresugammadex - Drug
Eligibility
18 - 89
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare two drugs used to reverse the effects of neuromuscular blockade agents after an outpatient bronchoscopy.

Eligible Conditions
  • Neuromuscular Blockade
  • Chronic Obstructive Pulmonary Disease (COPD)

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 1-30 minutes

1-20 minutes
number of minutes to return of baseline muscle tone
1-30 minutes
number of minutes to extubation

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Neostigmine/Glycopyrrolate
1 of 2
Sugammadex
1 of 2

Active Control

80 Total Participants · 2 Treatment Groups

Primary Treatment: Neostigmine/Glycopyrrolate · No Placebo Group · Phase 4

Neostigmine/Glycopyrrolate
Drug
ActiveComparator Group · 1 Intervention: neostigmine/glycopyrrolate · Intervention Types: Drug
Sugammadex
Drug
ActiveComparator Group · 1 Intervention: sugammadex · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1-30 minutes

Who is running the clinical trial?

Temple UniversityLead Sponsor
269 Previous Clinical Trials
74,295 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,676 Previous Clinical Trials
4,955,754 Total Patients Enrolled
35 Trials studying Neuromuscular Blockade
42,818 Patients Enrolled for Neuromuscular Blockade
Ellen Hauck, DO PhDPrincipal InvestigatorLewis Katz School of Medicine at Temple University

Eligibility Criteria

Age 18 - 89 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a glomerular filtration rate of at least 30 ml/min.
You have a diagnosis of COPD or ILD.